News Details - novonordisk.com
Sep 20, 2024 · Novo Nordisk A/S: Monlunabant phase 2a trial in obesity successfully completed. Bagsværd, Denmark, 20 September 2024 – Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral cannabinoid receptor 1 …
Novo Nordisk A/S: Monlunabant phase 2a trial in obesity …
Sep 20, 2024 · Monlunabant, formerly INV-202, was part of the acquisition of Inversago Pharmaceuticals Inc. announced in August 2023 [Link]. The trial investigated the efficacy and safety of a once-daily 10 mg,...
Monlunabant phase 2a trial in obesity successfully completed
Sep 20, 2024 · Monlunabant phase 2a trial in obesity successfully completed. Bagsværd, Denmark, 20 September 2024 – Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral cannabinoid receptor 1 …
Novo Nordisk's Monlunabant Data Drags Stocks Of Smaller Players
Sep 20, 2024 · Earlier on Friday, Novo Nordisk A/S (NYSE:NVO) announced headline results from a phase 2a clinical trial with monlunabant, a small-molecule oral cannabinoid receptor 1 (CB1) inverse agonist.
Novo Nordisk shares drop nearly 5% on disappointing obesity pill …
Sep 20, 2024 · Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental obesity pill monlunabant came in below market expectations.
Novo Nordisk A/S: Monlunabant phase 2a trial in obesity …
Bagsværd, Denmark, 20 September 2024 – Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral cannabinoid receptor 1 (CB1) inverse...
Novo Nordisk shares phase 2a trial data for obesity treatment
Sep 20, 2024 · Novo Nordisk has completed its phase 2a clinical trial of monlunabant, an oral cannabinoid receptor 1 (CB1) inverse agonist, for obesity treatment. The study included 243 participants with obesity and metabolic syndrome, testing daily doses of …
Novo’s Next-Gen CB1 Drug Leads to Weight Loss in Phase II, but ...
Sep 20, 2024 · Monlunabant, a small molecule oral cannabinoid receptor 1 (CB1) inverse agonist, has cut weight by 15 lbs after 16 weeks of treatment, compared to just 1.5 lbs for placebo, according to a Friday press release.
Questions over Novo Nordisk $1bn weight loss drug after Phase …
Sep 23, 2024 · The pharma giant announced results from the study (NCT05891834) which investigated monlunabant, a small molecule oral cannabinoid receptor 1 (CB1) inverse agonist acquired in the $1bn Inversago...
Novo Shares Fall on Safety Data for New Weight-Loss Drug - Bloomberg.com
Sep 20, 2024 · Monlunabant is an experimental compound that targets type 1 cannabinoid receptors, or CB1 receptors. The drug uses a similar approach to rimonabant, an obesity drug that European regulators...